Extended Data Fig. 6: Evaluation of metastasis markers in cancer cell lines and patient samples.
(a) Box plots showing the log2(FC) between metastatic and primary cell lines of anti- (N = 37) and pro-metastasis (N = 35) marker RPPA expression. The p-value is based on the Wilcoxon test. The middle line in the box is the median, the bottom and top of the box are the first and third quartiles, and the whiskers extend to the 1.5× interquartile range of the lower and the upper quartiles, respectively. N represents the number of protein markers in each group. (b, c) Relative mRNA level of CDK9 in CDK9-KD and control MD-MB-231 or A549 cells. N = 3 independent replicates were examined for each perturbation. Data are shown as mean ± SEM. (d, e) ROC curves showing predictive powers of GCLM expression in ACC patients (N = 44) (d) and CHK1 in SARC patients (N = 223) (e) between metastatic and non-metastatic primary tumor samples. N represents the number of patients. (f) A pie chart showing the distribution of drug development levels for all the identified pro-metastasis protein markers. The annotation data was obtained from the Pharos database. N represents the number of protein markers in each group (Tclin: N = 6; Tchem: N = 13; and Tbio: N = 15).
